title: Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.
abstract: Allogeneic hematopoietic stem cell transplantation has been well established for several decades as gene replacement therapy for patients with thalassemia major, and now offers very high rates of cure for patients who have access to this therapy. Outcomes have improved tremendously over the last decade, even in high-risk patients. The limited data available suggests that the long-term outcome is also excellent, with a >90% survival rate, but for the best results, hematopoietic stem cell transplantation should be offered early, before any end organ damage occurs. However, access to this therapy is limited in more than half the patients by the lack of suitable donors. Inadequate hematopoietic stem cell transplantation services and the high cost of therapy are other reasons for this limited access, particularly in those parts of the world which have a high prevalence of this condition. As a result, fewer than 10% of eligible patients are actually able to avail of this therapy. Other options for curative therapies are therefore needed. Recently, gene correction of autologous hematopoietic stem cells has been successfully established using lentiviral vectors, and several clinical trials have been initiated. A gene editing approach to correct the β-globin mutation or disrupt the BCL11A gene to increase fetal hemoglobin production has also been reported, and is expected to be introduced in clinical trials soon. Curative possibilities for the major hemoglobin disorders are expanding. Providing access to these therapies around the world will remain a challenge.
authors.affiliation: Department of Haematology & Centre for Stem Cell Research (a unit of inStem, Bengaluru), Christian Medical College, Vellore- 632004, Tamil Nadu, India aloks@cmcvellore.ac.in.
authors.forename: Alok
authors.initials: A
authors.lastname: Srivastava
authors.affiliation: Department of Haematology & Centre for Stem Cell Research (a unit of inStem, Bengaluru), Christian Medical College, Vellore- 632004, Tamil Nadu, India.
authors.forename: Ramachandran V
authors.initials: RV
authors.lastname: Shaji
mesh_terms: D000818:Animals; D000072669:Gene Editing; D015316:Genetic Therapy / Q000379:methods; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000378:metabolism*; D006801:Humans; D019172:Transplantation Conditioning; D016896:Treatment Outcome; D055544:beta-Globins / Q000235:genetics; D017086:beta-Thalassemia / Q000235:genetics / Q000628:therapy*
chemical_list: D055544:beta-Globins